Eksentricity

• $3M SBIR Grant Awarded: PsychoGenics, a New Jersey-based biotech firm specializing in AI-driven drug discovery, received a $3M SBIR Grant from the National Institute of Mental Health (NIMH).
• eCube® Platform Development: The funding will be used to enhance PsychoGenics’ proprietary AI-enabled EEG platform, eCube®, and its machine learning tools, aimed at identifying new applications for existing drugs targeting rare diseases.
• Innovative Drug Discovery: PsychoGenics’ platforms, including SmartCube®, NeuroCube®, and PhenoCube®, have led to the discovery of novel compounds now in advanced preclinical development and clinical trials.

Impact

1. Accelerated Drug Discovery: The grant will enable PsychoGenics to further develop its AI-powered platforms, potentially leading to faster identification of novel drug applications and advancements in treating rare diseases.
2. Advancement in Neurological Research: PsychoGenics’ focus on neurological disorders, including Huntington’s, Alzheimer’s, and autism, could result in breakthroughs that significantly impact patient care.
3. Strengthened Partnerships: The company’s shared-risk partnerships with major pharmaceutical companies, like Roche and Karuna, are likely to benefit from these advancements, potentially leading to new collaborative projects.
4. Enhanced AI Capabilities: By refining its machine learning tools and EEG platform, PsychoGenics is poised to push the boundaries of phenotypic drug discovery, setting new standards in the biotechnology industry.
5. Increased Focus on Rare Diseases: The development of eCube® for rare disease applications aligns with a growing industry focus on orphan drugs, addressing unmet medical needs in niche markets.

Read more